These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9651147)

  • 1. Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature.
    Wade WE
    Thromb Res; 1998 Feb; 89(4):199-202. PubMed ID: 9651147
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylaxis of venous thromboembolism in stroke patients.
    Turpie AG
    Semin Thromb Hemost; 1997; 23(2):155-7. PubMed ID: 9200340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 5. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease.
    Bergqvist D
    Aust N Z J Surg; 1998 Jul; 68(7):463-8. PubMed ID: 9669358
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
    Wade WE
    Am J Orthop (Belle Mead NJ); 1999 Apr; 28(4):229-31. PubMed ID: 10220094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate use of anticoagulants may not improve stroke outcomes.
    Am J Health Syst Pharm; 1998 Jun; 55(12):1240. PubMed ID: 9640462
    [No Abstract]   [Full Text] [Related]  

  • 9. Danaparoid is not a low-molecular-weight heparin.
    Nicholson CD; Meuleman DG; Magnani HN; Egberts JF; Leibowitz DA; Spinler SA; Cziraky MJ
    Am J Hosp Pharm; 1994 Aug; 51(16):2049-50. PubMed ID: 7526686
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrence of venous thromboembolism after treatment with unfractionated heparin.
    Sutton SK
    Ann Intern Med; 1996 Mar; 124(5):532. PubMed ID: 8602716
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis of APC resistance in patients on standard or low molecular weight heparin.
    Gilmore G; Thom J; Baker RI
    Thromb Haemost; 1996 Feb; 75(2):372-3. PubMed ID: 8815593
    [No Abstract]   [Full Text] [Related]  

  • 12. Classification of subtypes of ischemic stroke: history of the trial of org 10172 in acute stroke treatment classification.
    Adams HP; Biller J
    Stroke; 2015 May; 46(5):e114-7. PubMed ID: 25813192
    [No Abstract]   [Full Text] [Related]  

  • 13. [Thrombosis, low-molecular-weight heparin-induced thrombocytopenia and labor].
    Lemesle FG; Mebroukine L; Ermacora P; Lhuillier P; Marfaing A; Wolf M
    Presse Med; 1998 Jan; 27(1):19. PubMed ID: 9767759
    [No Abstract]   [Full Text] [Related]  

  • 14. Inter-assay and instrument variability of anti-Xa--results.
    Kovacs MJ; Keeney M
    Thromb Haemost; 2000 Jul; 84(1):138. PubMed ID: 10928485
    [No Abstract]   [Full Text] [Related]  

  • 15. Orgaran in the prevention of deep vein thrombosis in stroke patients.
    Turpie AG
    Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
    Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
    Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia and antithrombotic therapy.
    Boon DM; Michiels JJ; Stibbe J; van Vliet HH; Kappers-Klunne MC
    Lancet; 1994 Nov; 344(8932):1296. PubMed ID: 7526097
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.